**Supplementary Table 2.** Genital and urinary tract infections†.

|  |  |  |
| --- | --- | --- |
| **Outcome** | **Sitagliptin****n=427** | **Dapagliflozin****n=514** |
| Genital infection | 0 (0%) | 34 (6.6%) |
| Urinary tract infection | 2 (0.5%) | 13 (2.5%) |
| †Data presented as number of patients (%). |